论文部分内容阅读
胰岛素样生长因子(IGF)系统存在于正常卵巢中,在正常和肿瘤细胞生物学中起重要作用。综述近年来国内外在IGF系统及其在卵巢癌发生发展及耐药等方面的研究,发现卵巢癌患者血清及组织中IGF-1及IGF-1R、IGFBP-2水平增高,而IGFBP-3水平降低。IGFBP-2水平在上皮性卵巢癌患者血清中增高并与CA125正相关,有望成为卵巢癌潜在的标志物。使用反义寡核苷酸技术在基因水平上高度选择性地抑制IGF-1、IGF-2或IGF受体的表达均可有效抑制肿瘤的生长,显示抗IGF-1受体的反义策略可提供治疗卵巢癌的新方法。胰岛素样生长因子系统与卵巢癌的关系值得进一步研究。
The insulin-like growth factor (IGF) system is present in the normal ovary and plays an important role in normal and tumor cell biology. This review summarizes the recent progress in the study of IGF system and its development in ovarian cancer and its drug resistance in ovarian cancer. It is found that the levels of IGF-1, IGF-1R and IGFBP-2 in serum and tissues of patients with ovarian cancer are increased, while IGFBP-3 reduce. IGFBP-2 levels in serum of patients with epithelial ovarian cancer increased and positively correlated with CA125, is expected to become a potential marker of ovarian cancer. The use of antisense oligonucleotide technology to highly selectively inhibit the expression of IGF-1, IGF-2 or IGF receptors at the genetic level effectively inhibits the growth of tumors and shows that antisense strategies against the IGF-1 receptor can Provide a new method of treatment of ovarian cancer. The relationship between insulin-like growth factor system and ovarian cancer deserves further study.